Abstracts Archive - Page 1864 of 2425 - ACR Meeting Abstracts

Abstract Number: 2817 • 2014 ACR/ARHP Annual Meeting
Histone Deacetylase One Contributes to the Auto-Aggressive Phenotype of Rheumatoid Arthritis
Sarah Hawtree¹, Munitta Muthana¹, J. Mark Wilkinson², Anthony G. Wilson¹ and Mohammed Akil³, ¹Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, ²Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, United Kingdom, ³Rheumatology Department, Sheffield South Yorkshire, United Kingdom
Background/Purpose Rheumatoid arthritis (RA) is a chronic, autoimmune, inflammatory disease that affects synovial joints. A key characteristic of RA is hyperplasia of fibroblast-like synoviocytes (FLS)…
Abstract Number: 2818 • 2014 ACR/ARHP Annual Meeting
SH2 Domain-Containing Phosphatase 2 Promotes Aggressiveness of Rheumatoid Fibroblast-like Synoviocytes
Stephanie M. Stanford¹, German R. Aleman Muench¹, Cristiano Sacchetti¹, Lifan Zeng², David L. Boyle³, Gen-Sheng Feng⁴, Zhong-Yin Zhang², Maripat Corr³, Gary S. Firestein³ and Nunzio Bottini¹, ¹Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ²Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, ³Division of Rheumatology, Allergy and Immunology, University of California at San Diego School of Medicine, La Jolla, CA, ⁴Pathology, University of California at San Diego Division of Biological Sciences, La Jolla, CA
Background/Purpose In rheumatoid arthritis (RA), fibroblast-like synoviocytes (FLS) that line joint synovial membranes aggressively invade the extracellular matrix, destroying cartilage and bone. Although this cell…
Abstract Number: 2819 • 2014 ACR/ARHP Annual Meeting
The YAP Pathway Regulates Fibroblast-like Synoviocyte Invasion
Beatrix Bartok, Division of Rheumatology, allergy and immunology, University of California, San Diego, La Jolla, CA
Background/Purpose: Fibroblast like synoviocytes (FLS) in RA possesses unique transformed phenotype, such as cartilage invasion that is maintained independent of cytokines and other inflammatory cells.…
Abstract Number: 2820 • 2014 ACR/ARHP Annual Meeting
Dual Role for B Cells in Promoting Bone Erosion in Rheumatoid Arthritis Via Effects on Osteoclast and Osteoblast Differentiation
Nida Meednu¹, Hengwei Zhang², Teresa Owen³, Lianping Xing⁴ and Jennifer H. Anolik⁵, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Pathology and Laboratory Medicine, University of Rochester, Rochester, NY, ³Rheumatology, University of Rochester, Rochester, NY, ⁴Pathology & Lab Medicine, University of Rochester, Rochester, NY, ⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose Rheumatoid arthritis (RA) is a systemic autoimmune disease that often leads to joint damage, a process mediated by an imbalance between bone resorption and…
Abstract Number: 2821 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety/Tolerability of Mavrilimumab, a Human GM-CSFRÃ¡ Monoclonal Antibody in Patients with Rheumatoid Arthritis
Gerd Burmester¹, Iain B. McInnes², Joel M. Kremer³, Pedro Miranda⁴, Mariusz Korkosz⁵, Jiri Vencovsky⁶, Andrea Rubbert-Roth⁷, Eduardo Mysler⁸, Sara Sandbach⁹, Matthew A. Sleeman¹⁰, Alex Godwood¹¹, David Close¹² and Michael Weinblatt¹³, ¹Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ²University of Glasgow, Glasgow, United Kingdom, ³Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁴Centro de Estudios Reumatologicos, Santiago, Chile, ⁵Inernal Medicine and Gerontology, Malopolskie Centrum Medyczne, Krakow, Poland, ⁶Rheumatology, Charles University Institute of Rheumatology, Praha, Czech Republic, ⁷Med Clinic I, University of Cologne, Koln, Germany, ⁸Rheumatology, OMI, Buenos Aires, Argentina, ⁹Clinical biologics, MedImmune Ltd, Cambridge, United Kingdom, ¹⁰Respiratory, Inflammation and Autoimmunity, MedImmune Ltd, Cambridge, United Kingdom, ¹¹Clinical Biostatics and Data Management, MedImmune Ltd, Cambridge, United Kingdom, ¹²Clinical Development, MedImmune Ltd, Cambridge, United Kingdom, ¹³Rheumatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in RA pathogenesis via myeloid and granulocyte cell lineage activation. In a prior Phase 2a study (NCT01050998), mavrilimumab,…
Abstract Number: 2822 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis
Edward C. Keystone¹, Peter C. Taylor², Mark C Genovese³, Douglas E. Schlichting⁴, Inmaculada De La Torre⁵, Scott D. Beattie⁴ and Terence Rooney⁴, ¹University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ²NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ³Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵AVDA. DE LA INDUSTRIA 30, Eli Lilly and Company, Alcobendas, Spain
Background/Purpose: Baricitinib is an oral inhibitor of JAK1/JAK2 being investigated as a treatment for rheumatoid arthritis (RA). In a phase 2b study, baricitinib treatment resulted…
Abstract Number: 2823 • 2014 ACR/ARHP Annual Meeting
Comparable Efficacy with Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study
Roy Fleischmann^1,2, Dennis L. Decktor³, Chunpeng Fan⁴, Hubert Van Hoogstraten⁵ and Mark C Genovese⁶, ¹Metroplax Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, TX, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Biostatistics, Sanofi, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ, ⁶Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose For patients with prior exposure to tumor necrosis factor-α inhibitor (TNF-I), the likelihood of response to subsequent treatment with a TNF-I declines with the…
Abstract Number: 2824 • 2014 ACR/ARHP Annual Meeting
A Profile of the Efficacy of Sarilumab Plus Methotrexate in Rheumatoid Arthritis Patients: Results of a 52-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study
Arthur Kavanaugh¹, Dennis L. Decktor², Chunpeng Fan³, Janet van Adelsberg², Renata Martincova⁴ and Mark C. Genovese⁵, ¹University of California San Diego, La Jolla, CA, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Biostatistics, Sanofi, Bridgewater, NJ, ⁴Sanofi Czech Republic, Prague, Czech Republic, ⁵Stanford University Medical Center, Palo Alto, CA
Background/Purpose Interleukin-6 (IL-6) regulates a diverse array of activities that may underlie systemic and local symptoms of rheumatoid arthritis (RA). The efficacy of sarilumab, a…
Abstract Number: 2825 • 2014 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Phase 3 Equivalence Trial Comparing the Etanercept Biosimilar, HD203, with Etanercept (Enbrel^®), in Combination with Methotrexate (MTX) in Patients with Rheumatoid Arthritis (RA)
Sang-Cheol Bae¹, Jinseok Kim², Jung-Yoon Choe³, Won Park⁴, So-Ra Lee⁵, Yongho Ahn⁶ and Yunjeong Seo⁷, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Internal Medicine, Jeju National University, Jeju, Korea, South Korea, ³Division of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁴Medicine/Rheumatology, Inha University Hospital, Incheon, South Korea, ⁵Clinical Development/Regulatory Affairs, Hanwha Chemical, Seoul, South Korea, ⁶R&D Center, Hanwha Chemical, Daejeon, South Korea, ⁷Clinical Development, Hanwha Chemical, Seoul, South Korea
Background/Purpose Etanercept is a recombinant fusion protein that blocks TNF activity. HD203 is a biosimilar of etanercept. In a double-blind, randomized study in healthy volunteers,…
Abstract Number: 2826 • 2014 ACR/ARHP Annual Meeting
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Not on Concomitant Methotrexate
Mark C. Genovese¹, Maria Greenwald², Christine Codding³, Mario H. Cardiel⁴, Anna Zubrzycka-Sienkiewicz⁵, Alan J. Kivitz⁶, Steve Wisseh⁷, Kathyjo Shay⁸ and Jay P. Garg⁸, ¹Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Desert Medical Advances, PALM DESERT, CA, ³Health Research of Oklahoma, Oklahoma City, OK, ⁴Centro de Investigacion Clinica de Morelia, Morelia, Mexico, ⁵ARS Rheumatica sp. Zo.o, Reumatika, Warszawa, Poland, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Biocis, Chicago, IL, ⁸Astellas Pharma Global Development, Northbrook, IL
Background/Purpose ASP015K is a novel oral Janus kinase (JAK) inhibitor in development for the treatment of rheumatoid arthritis (RA). ASP015K inhibits JAK 1/3 with relative…
Abstract Number: 2827 • 2014 ACR/ARHP Annual Meeting
Cervical Spine Fracture and Mortality in Ankylosing Spondylitis
Katherine D. Wysham¹, Sara G. Murray², Nancy K. Hills³, Edward H. Yelin⁴ and Lianne S. Gensler⁵, ¹Internal Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁴Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁵Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Little data exist regarding mortality in Ankylosing Spondylitis (AS) patients. We performed a population-based study of diagnoses associated with hospital mortality in AS. Methods:…
Abstract Number: 2828 • 2014 ACR/ARHP Annual Meeting
A Physically Demanding Job May Amplify the Effect of Disease Activity on the Development of Syndesmophytes in Patients with Ankylosing Spondylitis
Sofia Ramiro^1,2, A.M. van Tubergen³, Robert Landewé^4,5, Annelies Boonen⁶, Carmen Stolwijk⁷, Maxime Dougados⁸, Filip van Den Bosch⁹ and Desiree van der Heijde¹⁰, ¹Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center/University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, Hospital Garcia de Orta, Almada, Portugal, ³Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Atrium Medical Center, Heerlen, Netherlands, ⁶Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁷Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁸Université Paris René Descartes and Hôpital Cochin, Paris, France, ⁹Ghent University Hospital, Ghent, Belgium, ¹⁰Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: We have recently shown that disease activity is longitudinally associated with radiographic progression in AS. In animal models, it has recently been shown that…
Abstract Number: 2829 • 2014 ACR/ARHP Annual Meeting
Spondyloarthritis Is Associated with Increased Cardiovascular and Cerebrovascular Mortality
Nigil Haroon¹, Nisha Nigil Haroon², Ping Li³, Michael Paterson³ and Robert D. Inman⁴, ¹Toronto Western Research Institute, Toronto, ON, Canada, ²Medicine, University of Toronto, Toronto, ON, Canada, ³Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, ⁴Immunlogy and Institute of Medical Science, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose OnSpA is a population-based study of spondyloarthritis (SpA) based on a provincial population of over 13 million. Patients with SpA are thought to be…
Abstract Number: 2830 • 2014 ACR/ARHP Annual Meeting
Progression to and Type of Orthopaedic Surgery in Juvenile Vs. Adult-Onset Ankylosing Spondylitis
Deepak R. Jadon¹, Gavin Shaddick², Amelia Jobling³, Athimalaipet V Ramanan⁴ and Raj Sengupta¹, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Mathematics, University of Bath, Bath, United Kingdom, ³Department of Mathematical Sciences, University of Bath, Bath, United Kingdom, ⁴Paediatric Rheumatology, University of Bristol Hospital Trust, Bristol, United Kingdom
Background/Purpose: Juvenile-onset ankylosing spondylitis (JoAS) and adult-onset ankylosing spondylitis (AoAS) are subtypes of ankylosing spondylitis (AS) that may have different clinical outcome. We compared cohorts…
Abstract Number: 2831 • 2014 ACR/ARHP Annual Meeting
Development of New Radiographic Vertebral Fractures in Patients with Ankylosing Spondylitis during 4 Years of TNF-α Blocking Therapy: Results from the Glas Cohort
Fiona Maas¹, Anneke Spoorenberg^1,2, Elisabeth Brouwer³, Reinhard Bos², Rizwana N. Chaudhry¹, Freke Wink², Hendrika Bootsma⁴, Eveline van der Veer⁵ and Suzanne Arends^2,4, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ³Dept. of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁵Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Previous studies have shown that the risk of vertebral fractures is increased in patients with ankylosing spondylitis (AS). Prospective longitudinal data about radiographic vertebral…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].